Pharmacological Mitigation of Fibrosis in a Porcine Model of Volumetric Muscle Loss Injury

Keyphrases

• Fibrosis 100%
• Porcine Model 100%
• Volumetric muscle Loss 100%
• Antifibrotic 70%
• Muscle Stiffness 40%
• Nintedanib 30%
• Skeletal muscle 20%
• Sham 20%
• Regenerative Medicine 20%
• Shear Wave Elastography 20%
• Longitudinal Analysis 10%
• Disability 10%
• Extremity Trauma 10%
• Muscle Function 10%
• Pathologic 10%
• Muscle Properties 10%
• Treatment Duration 10%
• Optimal Timing 10%
• Ultrasound Device 10%
• Large Animal Model 10%
• Stiffness 10%
• Fibrous Tissue 10%
• Defect Area 10%
• Primary Outcome Measure 10%
• Yorkshire 10%
• Optimal Duration 10%
• Quantitative Ultrasound 10%
• Hydroxyproline 10%
• Functional Deficits 10%
• Fibrotic Response 10%
• Biochemical Assessment 10%
• Tissue Deposition 10%
• Tissue Stiffness 10%
• Treatment Timing 10%
• Compartment Volumes 10%
• Genetic Investigation 10%
• Maximal Torque 10%
• Peroneal Nerve Stimulation 10%

Medicine and Dentistry

• Fibrosis 100%
• Nintedanib 57%
• Muscle Rigidity 42%
• Medicine 28%
• Elastography 28%
• Skeletal Muscle 28%
• Limb Injury 14%
• Neurostimulation 14%
• Muscle Function 14%
• Treatment Duration 14%
• Antifibrotic Agent 14%
• Hydroxyproline 14%
• Primary Outcome 14%

Pharmacology, Toxicology and Pharmaceutical Science

• Porcine Model 100%
• Fibrosis 100%
• Nintedanib 57%
• Muscle Rigidity 42%
• Limb Injury 14%
• Antifibrotic Agent 14%
• Hydroxyproline 14%